This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

IASLC-ACLC, Guangzhou, China, 08-10 November 2018

Afatinib named patient use program in advanced NSCLC with progression on prior therapy: experience from Asian center

Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, Yuh-Min Chen, Jin-Yuan Shih, Shyam Aggarwal, Shuhang Wang, Sang-We Kim, Young-Chul Kim, Ibrahim Wahid, Rubi Li, Wan-Teck Lim,
Virote Sriuranpong, Tsz Tong Chan, James Chih-Hsin Yang, Chong-Jen Yu, Wei-Yu Liao, Chao-Chi Ho, Robert M. Lorence, Philippe Carriere, Christina Raabe, Agnieszka Cseh, Keunchil Park


Learn more about the science behind this poster in the videos, papers and other materials below.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Cappuzzo F, et al. Future Oncol. 2018 Jun;14(15):1477-1486.

Activity of afatinib in heavily pre-treated patients with HER2 mutation-positive advanced NSCLC: findings from a global NPU programme

Peters S, et al. ESMO 2017 Poster Landing Page (

Named patient use program for afatinib in advanced NSCLC with progression on prior therapy: experience from Asian centers

Chang et al. WCLC 2018 Poster P1.01-11


In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.